Joon Lee, MD
Radiation Oncology · Bismarck, NDNPI 1396164208
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $844 of the $1,369 with a category attached, or 61.6%. 26 manufacturers reported payments, led by AstraZeneca at 41.2% of the total. 2024 is the largest year on record at $722, more than ten times the $14 reported in 2019.
Across 43 payments — averaging $31.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$565
- Sirtex Medical Inc$142
- Eisai Inc.$54
- Johnson & Johnson$47
- Amgen$46
- Siemens Medical Solutions USA, Inc.$39
- plus $476 from 20 others
What the payments were for
- Consulting fees$52538%
- Food & beverage$84462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $565 |
| Sirtex Medical Inc | 1 | $142 |
| Eisai Inc. | 4 | $54 |
| Johnson & Johnson | 3 | $47 |
| Amgen | 3 | $46 |
| Siemens Medical Solutions USA, Inc. | 1 | $39 |
| Seagen Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Agios Pharmaceuticals, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Sanofi | 2 | $32 |
| Boston Scientific | 1 | $30 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Incyte Corporation | 2 | $29 |
| Merck | 2 | $24 |
| Novocure Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| G1 Therapeutics, Inc. | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $12 |
| Morphosys, US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$525
- SIR-Spheres Microspheres$142
How this compares
$1,369 in reported general payments places this provider in the 80th percentile of 20 radiation oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 18 | $235 |
| Memantine Hcl | 11 | $138 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Bismarck
- Robert ReynoldsBismarck$2K
- Cole KreofskyBismarck$140
- John WatkinsBismarck$37
- Tarek DufanBismarck$21
- William NoyesGrand Forks$1.9M
- Grant SeegerGrand Forks$31K
- Michael GrantMinot$1K
- Salah DajaniFargo$508
- Jason HirshbergMinot$290
- Sommer NurkicFargo$216
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.